Efficient Hit-Finding Approaches for Histone Methyltransferases:The Key Parameters

Journal of Biomolecular Screening

Volumn 17, Issue 1, 2012, Pages 85-98

  Ahrens, Thomas ^a   Bergner, Andreas ^a   Hafenbradl, Doris ^a   Sheppard, David ^a  

^a BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EHMT2 PROTEIN, HUMAN; ENZYME INHIBITOR; HISTOCOMPATIBILITY ANTIGEN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; LIGAND;

ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLUORESCENCE; GENETIC EPIGENESIS; HIGH THROUGHPUT SCREENING; IC 50; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; RADIOMETRY; REPRODUCIBILITY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HISTOCOMPATIBILITY ANTIGENS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; INHIBITORY CONCENTRATION 50; LIGANDS; RADIOMETRY; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 84861819196     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111422823     Document Type: Article

References (74)

1. Goldberg A. D. Allis C. D. Bernstein E. Epigenetics: A Landscape Takes Shape. Cell 2007, 128, 635–638.
2. Strahl B. D. Allis C. D. The Language of Covalent Histone Modifications. Nature 2000, 403, 41–45.
3. Gardner K. E. Allis C. D. Strahl B. D. OPERating ON Chromatin, a Colorful Language Where Context Matters. J. Mol. Biol. 2011, 409, 36–46.
4. Martin C. Zhang Y. The Diverse Functions of Histone Lysine Methylation. Nat. Rev. Mol. Cell Biol. 2005, 6, 838–849.
5. Jones P. A. Baylin S. B. The Epigenomics of Cancer. Cell 2007, 128, 683–692.
6. Wilson C. B. Rowell E. Sekimata M. Epigenetic Control of T-Helper-Cell Differentiation. Nat. Rev. Immunol. 2009, 9, 91–105.
7. Tsankova N. Renthal W. Kumar A. Nestler E. J. Epigenetic Regulation in Psychiatric Disorders. Nat. Rev. Neurosci. 2007, 8, 355–367.
8. Simon J. A. Lange C. A. Roles of the EZH2 Histone Methyltransferase in Cancer Epigenetics. Mutat. Res. 2008, 647, 21–29.
9. Jansson M. Durant S. T. Cho E. C. Sheahan S. Edelmann M. Kessler B. La Thangue N. B. Arginine Methylation Regulates the p53 Response. Nat. Cell Biol. 2008, 10, 1431–1439.
10. Schneider R. Bannister A. J. Kouzarides T. Unsafe SETs: Histone Lysine Methyltransferases and Cancer. Trends Biochem. Sci. 2002, 27, 396–402.
11. Smith B. C. Denu J. M. Chemical Mechanisms of Histone Lysine and Arginine Modifications. Biochim. Biophys. Acta 2009, 1789, 45–57.
12. Copeland R. A. Solomon M. E. Richon V. M. Protein Methyltransferases as a Target Class for Drug Discovery. Nat. Rev. Drug Discov. 2009, 8, 724–732.
13. Vedel M. Lawrence F. Robert-Gero M. Lederer E. The Antifungal Antibiotic Sinefungin as a Very Active Inhibitor of Methyltransferases and of the Transformation of Chick Embryo Fibroblasts by Rous Sarcoma Virus. Biochem. Biophys. Res. Commun. 1978, 85, 371–376.
14. Spannhoff A. Heinke R. Bauer I. Trojer P. Metzger E. Gust R. Schüle R. Brosch G. Sippl W. Jung M. Target-Based Approach to Inhibitors of Histone Arginine Methyltransferases. J. Med. Chem. 2007, 50, 2319–2325.
15. Allan M. Manku S. Therrien E. Nguyen N. Styhler S. Robert M. F. Goulet A. C. Petschner A. J. Rahil G. Robert Macleod A. N-Benzyl-1-Heteroaryl-3-(trifluoromethyl)-1H-Pyrazole-5-Carboxamides as Inhibitors of Co-activator Associated Arginine Methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 2009, 19, 1218–1223.
16. Kubicek S. O’Sullivan R. J. August E. M. Hickey E. R. Zhang Q. Teodoro M. L. Rea S. Mechtler K. Kowalski J. A. Homon C. A. Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase. Mol. Cell 2007, 25, 473–481.
17. Liu F. Chen X. Allali-Hassani A. Quinn A. M. Wasney G. A. Dong A. Barsyte D. Kozieradzki I. Senisterra G. Chau I. Discovery of a 2,4-Diamino-7-Aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. J. Med. Chem. 2009, 52, 7950–7953.
18. Liu F. Chen X. Allali-Hassani A. Quinn A. M. Wigle T. J. Wasney G. A. Dong A. Senisterra G. Chau I. Siarheyeva A. Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-Aminoalkoxy-Quinazolines. J. Med. Chem. 2010, 53, 5844–5857.
19. Shinkai Y. Tachibana M. H3K9 Methyltransferase G9a and the Related Molecule GLP. Genes Dev. 2011, 25, 781–788.
20. Tachibana M. Sugimoto K. Nozaki M. Ueda J. Ohta T. Ohki M. Fukuda M. Takeda N Niida H. Kato H. G9a Histone Methyltransferase Plays a Dominant Role in Euchromatic Histone H3 Lysine 9 Methylation and Is Essential for Early Embryogenesis. Genes Dev. 2002, 16, 1779–1791.
21. Patnaik D. Chin H. G. Esteve P. O. Benner J. Jacobsen S. E. Pradhan S. Substrate Specificity and Kinetic Mechanism of Mammalian G9a Histone H3 Methyltransferase. J. Biol. Chem. 2004, 279, 53248–53258.
22. Tachibana M. Sugimoto K. Fukushima T. Shinkai Y. Set Domain-Containing Protein, G9a, Is a Novel Lysine-Preferring Mammalian Histone Methyltransferase with Hyperactivity and Specific Selectivity to Lysines 9 and 27 of Histone H3. J. Biol. Chem. 2001, 276, 25309–25317.
23. Rathert P. Dhayalan A. Murakami M. Zhang X. Tamas R. Jurkowska R. Komatsu Y. Shinkai Y. Cheng X. Jeltsch A. Protein Lysine Methyltransferase G9a Acts on Non-Histone Targets. Nat. Chem. Biol. 2008, 4, 344–346.
24. Sampath S. C. Marazzi I. Yap K. L. Sampath S. C. Krutchinsky A. N. Mecklenbrauker I. Viale A. Rudensky E. Zhou M. M. Chait B. T. Methylation of a Histone Mimic within the Histone Methyltransferase G9a Regulates Protein Complex Assembly. Mol. Cell 2007, 27, 596–608.
25. Feldman N. Gerson A. Fang J. Li E. Zhang Y. Shinkai Y. Cedar H. Bergman Y. G9a-Mediated Irreversible Epigenetic Inactivation of Oct-3/4 during Early Embryogenesis. Nat. Cell Biol. 2006, 8, 188–194.
26. Gyory I. Wu J. Fejer G. Seto E. Wright K. L. PRDI-BF1 Recruits the Histone H3 Methyltransferase G9a in Transcriptional Silencing. Nat. Immunol. 2004, 5, 299–308.
27. Boulias K. Talianidis I. Functional Role of G9a-Induced Histone Methylation in Small Heterodimer Partner-Mediated Transcriptional Repression. Nucleic Acids Res. 2004, 32, 6096–6103.
28. Fang S. Miao J. Xiang L. Ponugoti B. Treuter E. Kemper J. K. Coordinated Recruitment of Histone Methyltransferase G9a and Other Chromatin-Modifying Enzymes in SHP-Mediated Regulation of Hepatic Bile Acid Metabolism. Mol. Cell Biol. 2007, 27, 1407–1424.
29. Roopra A. Qazi R. Schoenike B. Daley T. J. Morrison J. F. Localized Domains of G9a-Mediated Histone Methylation Are Required for Silencing of Neuronal Genes. Mol. Cell 2004, 14, 727–738.
30. Lee D. Y. Northrop J. P. Kuo M. H. Stallcup M. R. Histone H3 Lysine 9 Methyltransferase G9a Is a Transcriptional Coactivator for Nuclear Receptors. J. Biol. Chem. 2006, 281, 8476–8485.
31. Chen M. W. Hua K. T. Kao H. J. Chi C. C. Wei L. H. Johansson G. Shiah S. G. Chen P. S. Jeng Y. M. Cheng T. Y. H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM. Cancer Res. 2010, 70, 7830–7840.
32. Kondo Y. Shen L. Ahmed S. Boumber Y. Sekido Y. Haddad B. R. Issa J. P. Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells. PLoS One 2008, 3, e2037.
33. Wozniak R. J. Klimecki W. T. Lau S. S. Feinstein Y. Futscher B. W. 5-Aza-2′-Deoxycytidine-Mediated Reductions in G9A Histone Methyltransferase and Histone H3 K9 Di-methylation Levels Are Linked to Tumor Suppressor Gene Reactivation. Oncogene 2007, 26, 77–90.
34. McInnes C. Virtual Screening Strategies in Drug Discovery. Curr. Opin. Chem. Biol. 2007, 11, 494–502.
35. Glick M. Jacoby E. The Role of Computational Methods in the Identification of Bioactive Compounds. Curr. Opin. Chem. Biol. 2011, 15, 1–7.
36. Ripphausen P. Nisius B. Peltason L. Bajorath J. Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications. J. Med. Chem. 2010, 53, 8461–8467.
37. Muegge I. Oloff S. Advances in Virtual Screening. Drug Discov. Today 2006, 3, 405–411.
38. Rester U. From Virtuality to Reality—Virtual Screening in Lead Discovery and Lead Optimization: A Medicinal Chemistry Perspective. Curr. Opin. Drug Discov. Dev. 2008, 11, 559–568.
39. Langer T. Hoffmann R. Bryant S. Lesur B. Hit Finding: Towards ‘Smarter’ Approaches. Curr. Opin. Pharmacol. 2009, 9, 589–593.
40. Clark D. E. What Has Virtual Screening Ever Done for Drug Discovery? Exp. Opin. Drug Discov. 2008, 3, 841–851.
41. Koppen H. Virtual Screening: What Does It Give Us? Curr. Opin. Drug Discov. Dev. 2009, 12, 397–407.
42. Schneider G. Virtual Screening: An Endless Staircase? Nat. Rev. Drug Discov. 2010, 9, 273–276.
43. Klebe G. Virtual Ligand Screening: Strategies, Perspectives and Limitations. Drug Discov. Today 2006, 11, 580–594.
44. Ripphausen P. Nisius B. Bajorath J. State-of-the-Art in Ligand-Based Virtual Screening. Drug Discov. Today 2011, 16, 372–376.
45. Eckert H. Bajorath J. Molecular Similarity Analysis in Virtual Screening: Foundations, Limitations and Novel Approaches. Drug Discov. Today 2007, 12, 225–233.
46. Leach A. R. Gillet V. J. Lewis R. A. Taylor R. Three-Dimensional Pharmacophore Methods in Drug Discovery. J. Med. Chem. 2010, 53, 539–558.
47. Wu H. Min J. Lunin V. V. Antoshenko T. Dombrovski L. Zeng H. Allali-Hassani A. Campagna-Slater V. Vedadi M. Arrowsmith C. H. Structural Biology of Human H3K9 Methyltransferases. PLoS One 2010, 5, e8570.
48. Maltman B. A. Dunsmore C. J. Couturier S. C. Tirnaveanu A. E. Delbederi Z. McMordie R. A. Naredo G. Ramage R. Cotton G. 9-Aminoacridine Peptide Derivatives as Versatile Reporter Systems for Use in Fluorescence Lifetime Assays. Chem. Commun. 2010, 46, 6929–6931.
49. Wigle T. J. Provencher L. M. Norris J. L. Jin J. Brown P. J. Frye S. V. Janzen W. P. Accessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis. Chem. Biol. 2010, 17, 695–704.
50. Rarey M. Dixon J. S. Feature Trees: A New Molecular Similarity Measure Based on Tree Matching. J. Comput. Aided Mol. Des. 1998, 12, 471–490.
51. Birchall K. Gillet V. J. Willett P. Ducrot P. Luttmann C. Use of Reduced Graphs to Encode Bioisosterism for Similarity-Based Virtual Screening. J. Chem. Inf. Model 2009, 49, 1330–1346.
52. Hert J. Willett P. Wilton D. J. Acklin P. Azzaoui K. Jacoby E. Schuffenhauer A. Enhancing the Effectiveness of Similarity-Based Virtual Screening Using Nearest-Neighbor Information. J. Med. Chem. 2005, 48, 7049–7054.
53. Bemis G. W. Murcko M. A. The Properties of Known Drugs: 1. Molecular Frameworks. J. Med. Chem. 1996, 39, 2887–2893.
54. Wagener M. Lommerse J. P. The Quest for Bioisosteric Replacements. J. Chem. Inf. Model 2006, 46, 677–685.
55. Berman H. M. Westbrook J. Feng Z. Gilliland G. Bhat T. N. Weissig H. Shindyalov I. N. Bourne P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242.
56. Bergner A. Günther J. Hendlich M. Klebe G. Verdonk M. Use of Relibase for Retrieving Complex Three-Dimensional Interaction Patterns Including Crystallographic Packing Effects. Biopolymers 2001, 61, 99–110.
57. Friesner R. A. Banks J. L. Murphy R. B. Halgren T. A. Klicic J. J. Mainz D. T. Repasky M. P. Knoll E. H. Shaw D. E. Shelley M. Glide: A New Approach for Rapid, Accurate Docking and Scoring: 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47, 1739–1749.
58. Halgren T. A. Murphy R. B. Friesner R. A. Beard H. S. Frye L. L. Pollard W. T. Banks J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring: 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750–1759.
59. Krammer A. Kirchhoff P. D. Jiang X. Venkatachalam C. M. Waldman M. LigScore: A Novel Scoring Function for Predicting Binding Affinities. J. Mol. Graph Model 2005, 23, 395–407.
60. Muegge I. Martin Y. C. A General and Fast Scoring Function for Protein-Ligand Interactions: A Simplified Potential Approach. J. Med. Chem. 1999, 42, 791–804.
61. Muegge I. PMF Scoring Revisited. J. Med. Chem. 2006, 49, 5895–5902.
62. Jain A. N. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine. J. Med. Chem. 2003, 46, 499–511.
63. Dhayalan A. Dimitrova E. Rathert P. Jeltsch A. A Continuous Protein Methyltransferase (G9a) Assay for Enzyme Activity Measurement and Inhibitor Screening. J. Biomol. Screen. 2009, 14, 1129–1133.
64. Zhang J. H. Chung T. D. Oldenburg K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67–73.
65. Reynolds C. H. Tounge B. A. Bembenek S. D. Ligand Binding Efficiency: Trends, Physical Basis, and Implications. J. Med. Chem. 2008, 51, 2432–2438.
66. Rea S. Eisenhaber F. O’Carroll D. Strahl B. D. Sun Z. W. Schmid M. Opravil S. Mechtler K. Ponting C. P. Regulation of Chromatin Structure by Site-Specific Histone H3 Methyltransferases. Nature 2000, 406, 593–599.
67. Best J. D. Carey N. Epigenetic Therapies for Non-Oncology Indications. Drug Discov. Today 2010, 15, 1008–1014.
68. Spannhoff A. Sippl W. Jung M. Cancer Treatment of the Future: Inhibitors of Histone Methyltransferases. Int. J. Biochem. Cell Biol. 2009, 41, 4–11.
69. Okada Y. Feng Q. Lin Y. Jiang Q. Li Y. Coffield V. M. Su L. Xu G. Zhang Y. hDOT1L Links Histone Methylation to Leukemogenesis. Cell 2005, 121, 167–178.
70. Comley J. Assay Interference a Limiting Factor in HTS? Drug Discov. World 2003, Summer, 91–98.
71. Harris C. J. Stevens A. P. Chemogenomics: Structuring the Drug Discovery Process to Gene Families. Drug Discov. Today 2006, 11, 880–888.
72. Crossley R. Slater M. A Reductionist Approach to Chemogenomics in the Design of Drug Molecules and Focused Libraries. Chemogenomics 2006, 4, 85–108.
73. Bergner A. Sheppard D. Slater M. EpiRoadmap: Integration of Chemogenomics-Based Approaches for Epigenetic Targets. SBS Conference 2011 Poster M200 2011.
74. Huang J. Dorsey J. Chuikov S. Perez-Burgos L. Zhang X. Jenuwein T. Reinberg D. Berger S. L. G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53. J. Biol. Chem. 2010, 285, 9636–9641.